
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
The authors review current industry practices and regulatory expectations for the aseptic processing of sterile drugs. They compare and outline critical issues in current manufacturing technology and capabilities with regulatory requirements.
almost 22 years ago
A Novel Freeze Pelletization Technique for Preparing Matix Pelletsalmost 22 years ago
Can Inserts Be Improved?almost 22 years ago
Drug Development Linked More Closely to Diagnosticsalmost 22 years ago
In The Spotlight-October 2004almost 22 years ago
October 2004almost 22 years ago
The High Price of Successalmost 22 years ago
Pharma Company Investment in Parenteral Manufacturing Capacity Picking Up





